Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Abacus Diagnostica's GenomeEra C. Difficile Assay


Abacus Diagnostica said recently that it has received the CE mark for the GenomEra C. difficile assay for the detection of toxin-producing Clostridium difficile directly from stool samples.

The GenomEra C. difficile assay is extremely simple to perform directly from stool specimen through a straightforward sample preparation process without extraction, heating or centrifugation steps, Abacus said. The assay is built on rapid and reliable target amplification and end-point detection technology that produces high-quality results in 50 minutes.

The assay runs on the GenomEra CDX system, a closed, self-contained, fully integrated and automated testing platform designed for clinical routine use. The platform combines minimal sample preparation with rapid PCR amplification and end-point detection. It is the first commercial homogenous PCR platform to use thermally stable, intrinsically fluorescent time-resolved fluorometric labels combined with a proprietary assay and measurement technology to eliminate background effects originating from, for example, clinical samples, the company said.

Filed under

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.